These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

181 related articles for article (PubMed ID: 32923836)

  • 1. Real-World Effectiveness of Obeticholic Acid in Patients with Primary Biliary Cholangitis.
    Roberts SB; Ismail M; Kanagalingam G; Mason AL; Swain MG; Vincent C; Yoshida EM; Tsien C; Flemming JA; Janssen HLA; Hirschfield GM; Hansen BE; Gulamhusein AF;
    Hepatol Commun; 2020 Sep; 4(9):1332-1345. PubMed ID: 32923836
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Real-world experience with obeticholic acid in patients with primary biliary cholangitis.
    D'Amato D; De Vincentis A; Malinverno F; Viganò M; Alvaro D; Pompili M; Picciotto A; Palitti VP; Russello M; Storato S; Pigozzi MG; Calvaruso V; De Gasperi E; Lleo A; Castellaneta A; Pellicelli A; Cazzagon N; Floreani A; Muratori L; Fagiuoli S; Niro GA; Feletti V; Cozzolongo R; Terreni N; Marzioni M; Pellicano R; Pozzoni P; Baiocchi L; Chessa L; Rosina F; Bertino G; Vinci M; Morgando A; Vanni E; Scifo G; Sacco R; D'Antò M; Bellia V; Boldizzoni R; Casella S; Omazzi B; Poggi G; Cristoferi L; Gerussi A; Ronca V; Venere R; Ponziani F; Cannavò M; Mussetto A; Fontana R; Losito F; Frazzetto E; Distefano M; Colapietro F; Labanca S; Marconi G; Grassi G; Galati G; O'Donnell SE; Mancuso C; Mulinacci G; Palermo A; Claar E; Izzi A; Picardi A; Invernizzi P; Carbone M; Vespasiani-Gentilucci U;
    JHEP Rep; 2021 Apr; 3(2):100248. PubMed ID: 33681748
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effectiveness and safety of obeticholic acid in a Southern European multicentre cohort of patients with primary biliary cholangitis and suboptimal response to ursodeoxycholic acid.
    Gomez E; Garcia Buey L; Molina E; Casado M; Conde I; Berenguer M; Jorquera F; Simón MA; Olveira A; Hernández-Guerra M; Mesquita M; Presa J; Costa-Moreira P; Macedo G; Arenas JI; Manuel Sousa J; Ampuero J; Morillas RM; Santos A; De Carvalho A; Uriz J; Carrión JA; Luisa Gutiérrez M; Pérez-Fernández E; Fernández-Rodríguez CM;
    Aliment Pharmacol Ther; 2021 Feb; 53(4):519-530. PubMed ID: 33314220
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Obeticholic acid is associated with improvements in AST-to-platelet ratio index and GLOBE score in patients with primary biliary cholangitis.
    Harms MH; Hirschfield GM; Floreani A; Mayo MJ; Parés A; Liberman A; Malecha ES; Pencek R; MacConell L; Hansen BE
    JHEP Rep; 2021 Feb; 3(1):100191. PubMed ID: 33319187
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Combination of fibrates with obeticholic acid is able to normalise biochemical liver tests in patients with difficult-to-treat primary biliary cholangitis.
    Soret PA; Lam L; Carrat F; Smets L; Berg T; Carbone M; Invernizzi P; Leroy V; Trivedi P; Cazzagon N; Weiler-Normann C; Alric L; Rosa-Hezode I; Heurgué A; Cervoni JP; Dumortier J; Potier P; Roux O; Silvain C; Bureau C; Anty R; Larrey D; Levy C; Pares A; Schramm C; Nevens F; Chazouillères O; Corpechot C
    Aliment Pharmacol Ther; 2021 May; 53(10):1138-1146. PubMed ID: 33764590
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A randomized, placebo-controlled, phase II study of obeticholic acid for primary sclerosing cholangitis.
    Kowdley KV; Vuppalanchi R; Levy C; Floreani A; Andreone P; LaRusso NF; Shrestha R; Trotter J; Goldberg D; Rushbrook S; Hirschfield GM; Schiano T; Jin Y; Pencek R; MacConell L; Shapiro D; Bowlus CL;
    J Hepatol; 2020 Jul; 73(1):94-101. PubMed ID: 32165251
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Development and Validation of a Scoring System to Predict Response to Obeticholic Acid in Primary Biliary Cholangitis.
    De Vincentis A; Ampuero J; Terracciani F; D'Amato D; Gerussi A; Cristoferi L; Cazzagon N; Bonaiuto E; Floreani A; Calvaruso V; Cadamuro L; Degasperi E; Morgando A; Vanni E; Lleo A; Colapietro F; Alvaro D; Castellaneta A; Labanca S; Viganò M; Distefano M; Pace Palitti V; Ricci C; De Matthaeis N; Marzioni M; Gómez-Dominguez E; Montero JL; Molina E; Garcia-Buey L; Casado M; Berenguer M; Conde I; Simon MA; Fuentes J; Costa-Moreira P; Macedo G; Jorquera F; Morillas RM; Presa J; Sousa JM; Gomes D; Santos L; Olveira A; Hernandez-Guerra M; Aburruza L; Santos A; Carvalho A; Uriz J; Gutierrez ML; Perez E; Chessa L; Pellicelli A; Marignani M; Muratori L; Niro GA; Brunetto M; Ponziani FR; Pompili M; Marra F; Galli A; Mussetto A; Alagna G; Simone L; Bertino G; Rosina F; Cozzolongo R; Russello M; Baiocchi L; Saitta C; Terreni N; Zolfino T; Rigamonti C; Vigano R; Cuccorese G; Pozzoni P; Pedone C; Grasso S; Picardi A; Invernizzi P; Sacco R; Izzi A; Fernandez-Rodriguez C; Vespasiani-Gentilucci U; Carbone M;
    Clin Gastroenterol Hepatol; 2024 Oct; 22(10):2062-2074.e11. PubMed ID: 38782175
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Obeticholic Acid and Fibrates in Primary Biliary Cholangitis: Comparative Effects in a Multicentric Observational Study.
    Reig A; Álvarez-Navascués C; Vergara M; Gómez-Domínguez E; Gallego-Moya A; Pérez-Medrano IM; Fábrega E; Hernández-Guerra M; Berenguer M; Estevez P; Arencibia A; Morillas RM; Horta D; Albillos A; Casado M; De la Cruz G; Fernandez-Bonilla E; Molina E; Hijona L; Diago M; Fernández-Rodriguez CM; González-Santiago JM; Sala M; Gómez-Camarero J; Romero-Gomez M; Suárez F; Vargas V; Ferre-Aracil C; Andrade RJ; Chahri N; Parés A
    Am J Gastroenterol; 2021 Nov; 116(11):2250-2257. PubMed ID: 34158466
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Greater Transplant-Free Survival in Patients Receiving Obeticholic Acid for Primary Biliary Cholangitis in a Clinical Trial Setting Compared to Real-World External Controls.
    Murillo Perez CF; Fisher H; Hiu S; Kareithi D; Adekunle F; Mayne T; Malecha E; Ness E; van der Meer AJ; Lammers WJ; Trivedi PJ; Battezzati PM; Nevens F; Kowdley KV; Bruns T; Cazzagon N; Floreani A; Mason AL; Parés A; Londoño MC; Invernizzi P; Carbone M; Lleo A; Mayo MJ; Dalekos GN; Gatselis NK; Thorburn D; Verhelst X; Gulamhusein A; Janssen HLA; Smith R; Flack S; Mulcahy V; Trauner M; Bowlus CL; Lindor KD; Corpechot C; Jones D; Mells G; Hirschfield GM; Wason J; Hansen BE;
    Gastroenterology; 2022 Dec; 163(6):1630-1642.e3. PubMed ID: 36150526
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Obeticholic acid for the treatment of primary biliary cholangitis.
    Ali AH; Lindor KD
    Expert Opin Pharmacother; 2016 Sep; 17(13):1809-15. PubMed ID: 27468093
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A randomized trial of obeticholic acid monotherapy in patients with primary biliary cholangitis.
    Kowdley KV; Luketic V; Chapman R; Hirschfield GM; Poupon R; Schramm C; Vincent C; Rust C; Parés A; Mason A; Marschall HU; Shapiro D; Adorini L; Sciacca C; Beecher-Jones T; Böhm O; Pencek R; Jones D;
    Hepatology; 2018 May; 67(5):1890-1902. PubMed ID: 29023915
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Farnesoid X receptor agonist tropifexor attenuates cholestasis in a randomised trial in patients with primary biliary cholangitis.
    Schramm C; Wedemeyer H; Mason A; Hirschfield GM; Levy C; Kowdley KV; Milkiewicz P; Janczewska E; Malova ES; Sanni J; Koo P; Chen J; Choudhury S; Klickstein LB; Badman MK; Jones D
    JHEP Rep; 2022 Nov; 4(11):100544. PubMed ID: 36267872
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Long-term efficacy and safety of obeticholic acid for patients with primary biliary cholangitis: 3-year results of an international open-label extension study.
    Trauner M; Nevens F; Shiffman ML; Drenth JPH; Bowlus CL; Vargas V; Andreone P; Hirschfield GM; Pencek R; Malecha ES; MacConell L; Shapiro D
    Lancet Gastroenterol Hepatol; 2019 Jun; 4(6):445-453. PubMed ID: 30922873
    [TBL] [Abstract][Full Text] [Related]  

  • 14. UK-Wide Multicenter Evaluation of Second-line Therapies in Primary Biliary Cholangitis.
    Abbas N; Culver EL; Thorburn D; Halliday N; Crothers H; Dyson JK; Phaw A; Aspinall R; Khakoo SI; Kallis Y; Smith B; Patanwala I; McCune A; Chimakurthi CR; Hegade V; Orrell M; Jones R; Mells G; Thain C; Thain RM; Jones D; Hirschfield G; Trivedi PJ
    Clin Gastroenterol Hepatol; 2023 Jun; 21(6):1561-1570.e13. PubMed ID: 35961518
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Long-term clinical impact and cost-effectiveness of obeticholic acid for the treatment of primary biliary cholangitis.
    Samur S; Klebanoff M; Banken R; Pratt DS; Chapman R; Ollendorf DA; Loos AM; Corey K; Hur C; Chhatwal J
    Hepatology; 2017 Mar; 65(3):920-928. PubMed ID: 27906472
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Clinical application of the GLOBE and United Kingdom-primary biliary cholangitis risk scores in a trial cohort of patients with primary biliary cholangitis.
    Carbone M; Harms MH; Lammers WJ; Marmon T; Pencek R; MacConell L; Shapiro D; Jones DE; Mells GF; Hansen BE
    Hepatol Commun; 2018 Jun; 2(6):683-692. PubMed ID: 29881820
    [TBL] [Abstract][Full Text] [Related]  

  • 17. RANK/RANKL Acts as a Protective Factor by Targeting Cholangiocytes in Primary Biliary Cholangitis.
    Hao YL; Bian ZL; Ju LL; Liu Y; Qin G
    Dig Dis Sci; 2020 Feb; 65(2):470-479. PubMed ID: 31377883
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Obeticholic acid for the treatment of primary biliary cholangitis in adult patients: clinical utility and patient selection.
    Bowlus CL
    Hepat Med; 2016; 8():89-95. PubMed ID: 27621676
    [TBL] [Abstract][Full Text] [Related]  

  • 19.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 20.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 10.